Robert M. Jotte
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Otorhinolaryngology top 0.5%
- Head and Neck Cancer Studies
Papers in
- Oncology 42
- Cancer Immunotherapy and Biomarkers 25
- Lung Cancer Research Studies 15
- Colorectal Cancer Treatments and Studies 5
- CAR-T cell therapy research 3
-
- Lung Cancer Treatments and Mutations 22
- Co-authors
- Mark A. Socinski (22 shared papers)Federico Cappuzzo (16 shared papers)Delvys Rodríguez‐Abreu (8 shared papers)Daniil Stroyakovskiy (7 shared papers)Martin Reck (7 shared papers)Gene Grant Finley (7 shared papers)Alan Sandler (3 shared papers)Denis Moro‐Sibilot (6 shared papers)
- Journals
- Journal of Thoracic Oncology (17 papers)Annals of Oncology (16 papers)Journal of Clinical Oncology (9 papers)Cancer Chemotherapy and Pharmacology (2 papers)Clinical Lung Cancer (2 papers)
- Partner nations
- United StatesItalyGermany
In The Last Decade
Robert M. Jotte
71 papers receiving 10.1k citations
Robert M. Jotte's Hit Papers
Peers
Comparison fields: 5 of 107
- Oncology 6.3k
- Otorhinolaryngology 868
- Pulmonary and Respiratory Medicine 3.4k
- Immunology 1.3k
- Cancer Research 767
Countries citing papers authored by Robert M. Jotte
This map shows the geographic impact of Robert M. Jotte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Jotte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Jotte more than expected).
Fields of papers citing papers by Robert M. Jotte
This network shows the impact of papers produced by Robert M. Jotte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Jotte. The network helps show where Robert M. Jotte may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert M. Jotte, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 74 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Hit paper breakdown → | 2018 | 3075 |
| 2 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 2460 |
| 3 | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Hit paper breakdown → | 2019 | 790 |
| 4 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Hit paper breakdown → | 2020 | 473 |
| 5 | IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC Hit paper breakdown → | 2021 | 389 |
| 6 | 2013 | 314 | |
| 7 | 2014 | 273 | |
| 8 | IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain Hit paper breakdown → | 2021 | 230 |
| 9 | 2018 | 203 | |
| 10 | 2012 | 174 | |
| 11 | 2020 | 168 | |
| 12 | 2019 | 153 | |
| 13 | 2010 | 140 | |
| 14 | 2023 | 130 | |
| 15 | 2022 | 117 | |
| 16 | 2010 | 101 | |
| 17 | 2017 | 90 | |
| 18 | 2008 | 87 | |
| 19 | 1985 | 54 | |
| 20 | 2009 | 54 |
About Robert M. Jotte
Robert M. Jotte is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Epidemiology and Immunology, having authored 74 papers that have together received 10.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (15 papers), Cancer Genomics and Diagnostics (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Neuroendocrine Tumor Research Advances (5 papers), Cancer therapeutics and mechanisms (4 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Oncology (6.3k citations), Otorhinolaryngology (868 citations), Pulmonary and Respiratory Medicine (3.4k citations), Immunology (1.3k citations) and Cancer Research (767 citations). Robert M. Jotte has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Mark A. Socinski, Federico Cappuzzo, Delvys Rodríguez‐Abreu, Daniil Stroyakovskiy, Martin Reck, Gene Grant Finley, Alan Sandler, Denis Moro‐Sibilot, Francesco Orlandi and Naoyuki Nogami. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.